Short time guided bone regeneration using beta-tricalcium phosphate with and without fibronectin - An experimental study in rats
Sánchez-Garcés MÁ., Camps-Font O., Escoda-Francolí J., Muñoz-Guzón F., Toledano-Serrabona J., Gay-Escoda C.
Animal Study, published in Med Oral Patol Oral Cir Bucal (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Med Oral Patol Oral Cir Bucal (2020)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 32388521
- PMCID
- PMC7338076
- DOI
- 10.4317/medoral.23564
- Citations
- 3
Abstract (original English)
Background The aim of this histomorphometric study was to assess the bone regeneration potential of beta-tricalcium phosphate with fibronectin (β-TCP-Fn) in critical-sized defects (CSDs) in rats calvarial, to know whether Fn improves the new bone formation in a short time scope. Material and methods CSDs were created in 30 Sprague Dawley rats, and divided into four groups (2 or 6 weeks of healing) and type of filling (β-TCP-Fn, β-TCP, empty control). Variables studied were augmented area (AA), gained tissue (GT), mineralized/non mineralized bone matrix (MBM/NMT) and bone substitute (BS). Results 60 samples at 2 and six weeks were evaluated. AA was higher for treatment groups comparing to controls (p Conclusions Both β-TCP biomaterials are effective as compared with bone defects left empty in maintaining the volume. GT in defects regeneration filed with β-TCP-Fn are significantly better in short healing time when comparing with controls but not for β-TCP used alone in rats calvarial CSDs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.